| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| Adjusting Measures of Economic Output for Health: Is the Business Cycle Countercyclical? |
0 |
0 |
0 |
0 |
0 |
0 |
6 |
8 |
| Adjusting National Accounting for Health: Is the Business Cycle Countercyclical? |
0 |
0 |
0 |
62 |
1 |
1 |
14 |
104 |
| Aging and the Growth of Long-Term Care |
0 |
0 |
1 |
31 |
0 |
0 |
7 |
152 |
| Aging and the Growth of Long-Term Care |
0 |
0 |
0 |
243 |
0 |
0 |
21 |
1,315 |
| An Economic Evaluation of the War on Cancer |
0 |
0 |
0 |
97 |
0 |
1 |
15 |
376 |
| An Empirical Examination of Information Barriers to Trade in Insurance |
0 |
1 |
1 |
1 |
0 |
3 |
17 |
1,066 |
| An Empirical Examination of Information Barriers to Trade in Insurance |
0 |
0 |
0 |
420 |
1 |
1 |
43 |
2,674 |
| Antitrust and the Not-For-Profit Sector |
0 |
0 |
0 |
321 |
0 |
1 |
11 |
1,059 |
| Antitrust in the Not-For-Profit Sector |
0 |
0 |
0 |
173 |
0 |
1 |
14 |
794 |
| Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process |
0 |
0 |
0 |
86 |
0 |
1 |
6 |
513 |
| Assessing the Safety and Efficacy of the FDA: The Case of the Prescription Drug User Fee Acts |
0 |
0 |
0 |
0 |
0 |
0 |
9 |
15 |
| Assessing the Safety and Efficacy of the FDA: The Case of the Prescription Drug User Fee Acts |
0 |
0 |
0 |
77 |
0 |
0 |
10 |
270 |
| Can Medical Progress be Sustained? Implications of the Link Between Development and Output Markets |
0 |
0 |
0 |
0 |
0 |
1 |
9 |
10 |
| Can Medical Progress be Sustained? Implications of the Link Between Development and Output Markets |
0 |
0 |
0 |
37 |
0 |
1 |
15 |
129 |
| Consumption vs. Production of Insurance |
0 |
0 |
0 |
108 |
1 |
3 |
16 |
781 |
| Cost-Benefit Analysis of the FDA: The Case of the Prescription Drug User Fee Acts |
0 |
0 |
1 |
2 |
0 |
0 |
17 |
22 |
| Data MArkets and OPtimal Sample Size Determination |
0 |
0 |
0 |
0 |
0 |
0 |
8 |
2,844 |
| Death, Tetanus and Aerobics: The Evaluation of Disease-Specific Health Interventions |
0 |
0 |
0 |
49 |
0 |
0 |
7 |
464 |
| Death, tetanus, and aerobics: The evaluation of disease-specific health interventions |
0 |
0 |
0 |
11 |
0 |
0 |
6 |
221 |
| Disease Complementarities and the Evaluation of Public Health Interventions |
0 |
0 |
0 |
124 |
0 |
0 |
5 |
907 |
| Disease Eradication: Private vs. Public Vaccination |
0 |
0 |
0 |
0 |
0 |
1 |
8 |
576 |
| Economic Analysis of Risk and Uncertainty induced by Health Shocks: A Review and Extension |
0 |
0 |
0 |
48 |
0 |
0 |
10 |
139 |
| Economic Epidemiology and Infectious Diseases |
1 |
2 |
2 |
920 |
1 |
2 |
14 |
2,759 |
| Endogenous Cost-Effectiveness Analysis in Health Care Technology Adoption |
0 |
0 |
0 |
57 |
0 |
0 |
6 |
311 |
| Estimating the Extent of Trade Under Incomplete Information: The Case of HIV |
0 |
0 |
0 |
0 |
0 |
0 |
5 |
139 |
| External Treatment Effects and Program Implementation Bias |
0 |
0 |
0 |
15 |
3 |
3 |
10 |
116 |
| External Treatment Effects and Program Implementation Bias |
0 |
0 |
0 |
76 |
0 |
0 |
9 |
552 |
| Financial Health Economics |
0 |
0 |
0 |
145 |
0 |
0 |
17 |
366 |
| Health Care Adherence and Personalized Medicine |
0 |
0 |
0 |
66 |
0 |
0 |
17 |
89 |
| Health Care, Technological Change, and Altruistic Consumption Externalities |
0 |
0 |
0 |
48 |
0 |
1 |
12 |
384 |
| Health investment complementarities under competing risks |
0 |
0 |
0 |
214 |
0 |
0 |
16 |
1,195 |
| How Does Technological Change Affect Quality-Adjusted Prices in Health Care? Systematic Evidence from Thousands of Innovations |
0 |
0 |
1 |
92 |
1 |
1 |
17 |
84 |
| Integrated Insurance Design in the Presence of Multiple Medical Technologies |
0 |
0 |
0 |
23 |
0 |
0 |
5 |
176 |
| Intellectual Property & External Consumption Effects: Generalizations From Health Care Markets |
0 |
0 |
0 |
1 |
0 |
0 |
9 |
12 |
| Intellectual Property & External Consumption Effects: Generalizations From Health Care Markets |
0 |
0 |
0 |
0 |
0 |
0 |
7 |
11 |
| Intellectual Property & External Consumption Effects: Generalizations from Pharmaceutical Markets |
0 |
0 |
0 |
151 |
1 |
1 |
13 |
572 |
| Intellectual Property and Marketing |
0 |
0 |
0 |
0 |
0 |
1 |
10 |
17 |
| Intellectual Property and Marketing |
0 |
0 |
0 |
91 |
2 |
5 |
21 |
414 |
| International Health Economics |
0 |
0 |
0 |
0 |
0 |
1 |
6 |
11 |
| International Health Economics |
0 |
0 |
0 |
47 |
0 |
1 |
6 |
89 |
| Is Health Care Technology Over-Approved? A Meta-Analysis of Revealed Preference |
0 |
0 |
0 |
0 |
0 |
2 |
3 |
183 |
| Is the Food and Drug Administration Safe and Effective? |
0 |
0 |
0 |
1 |
0 |
0 |
9 |
13 |
| Is the Food and Drug Administration Safe and Effective? |
0 |
0 |
0 |
78 |
1 |
1 |
15 |
289 |
| Is the Obesity Epidemic a Public Health Problem? A Decade of Research on the Economics of Obesity |
0 |
0 |
1 |
407 |
2 |
3 |
15 |
1,279 |
| Merit Motives & Government Intervention: Public Finance in Reverse |
0 |
0 |
0 |
123 |
0 |
0 |
13 |
639 |
| Merit Motives and Government Intervention: Public Finance in Reverse |
0 |
0 |
1 |
204 |
0 |
3 |
10 |
872 |
| Merit Motives and Government Intervention: Public Finance in Reverse |
0 |
0 |
1 |
125 |
0 |
2 |
19 |
1,172 |
| Mortality Contingent Claims, Health Care, and Social Insurance |
0 |
0 |
0 |
2 |
0 |
1 |
8 |
1,180 |
| Mortality Contingent Claims, Health Care, and Social Insurance |
0 |
0 |
0 |
162 |
0 |
0 |
8 |
606 |
| Nonprofit Production |
0 |
0 |
0 |
0 |
0 |
1 |
9 |
205 |
| Nonprofit Production and Competition |
0 |
0 |
0 |
301 |
0 |
1 |
16 |
1,274 |
| Observational Agency and Supply-Side Econometrics |
0 |
0 |
0 |
28 |
0 |
1 |
7 |
396 |
| Pricing and R&D with Related Margins |
0 |
0 |
0 |
0 |
1 |
1 |
9 |
572 |
| Public Liabilities and Health Care Policy |
0 |
0 |
0 |
32 |
1 |
1 |
6 |
107 |
| Rational Epidemics and their Public Control |
0 |
0 |
0 |
0 |
1 |
2 |
16 |
648 |
| Self-Interested Treatment Evaluation in Experiments |
0 |
0 |
0 |
0 |
0 |
0 |
8 |
118 |
| Sharing R&D Risk in Healthcare via FDA Hedges |
0 |
0 |
1 |
30 |
0 |
0 |
20 |
114 |
| Surplus Appropriation from R&D and Health Care Technology Assessment Procedures |
0 |
0 |
0 |
72 |
0 |
1 |
21 |
399 |
| Surplus Appropriation from R&D and Health Care Technology Assessment Procedures |
0 |
0 |
1 |
106 |
0 |
17 |
25 |
687 |
| Terminal Care and The Value of Life Near Its End |
0 |
1 |
4 |
214 |
1 |
2 |
20 |
718 |
| The Dual Effects of Intellectual Property Regulations: Within- and Between- Patent Competition in the US Pharmaceuticals Industry |
0 |
0 |
0 |
283 |
0 |
0 |
9 |
956 |
| The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in The US Pharmaceuticals Industry |
0 |
0 |
0 |
0 |
0 |
1 |
9 |
14 |
| The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the US |
0 |
0 |
0 |
38 |
1 |
1 |
12 |
148 |
| The Economic Value of Eliminating Cancer |
0 |
0 |
19 |
19 |
1 |
6 |
26 |
26 |
| The Effects of Product Liability Exemption in the Presence of the FDA |
0 |
0 |
0 |
19 |
0 |
1 |
7 |
204 |
| The Future of Old-Age Longevity: Competitive Pricing of Morality Contingent Claims |
0 |
0 |
0 |
0 |
0 |
1 |
8 |
1,006 |
| The Future of Old-Age Longevity: Competitive Pricing of Mortality Contingent Claims |
0 |
0 |
0 |
68 |
1 |
2 |
6 |
351 |
| The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination |
0 |
0 |
0 |
492 |
0 |
2 |
20 |
1,624 |
| The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination |
0 |
0 |
0 |
89 |
0 |
0 |
15 |
387 |
| The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination |
0 |
0 |
0 |
0 |
0 |
1 |
14 |
20 |
| The Impact of Comparative Effectiveness Research on Health and Health Care Spending |
0 |
0 |
0 |
57 |
1 |
1 |
12 |
241 |
| The Long-Run Growth in Obesity as a Function of Technological Change |
0 |
1 |
1 |
596 |
0 |
2 |
11 |
2,288 |
| The Long-Run Growth in Obesity as a Function of Technological Change |
0 |
0 |
0 |
90 |
1 |
2 |
15 |
359 |
| The Private Demand for Information and the Effects of Public Testing Programs: The Case of HIV |
0 |
0 |
0 |
0 |
0 |
1 |
3 |
460 |
| The Quantity and Quality of Life and the Evolution of World Inequality |
0 |
0 |
0 |
919 |
1 |
2 |
22 |
2,716 |
| The Rise in Old Age Longevity and the Market for Long-Term Care |
0 |
0 |
0 |
234 |
0 |
0 |
11 |
1,788 |
| The Rise in Old Age Longevity and the Market for Long-Term Care |
0 |
0 |
0 |
3 |
0 |
2 |
10 |
781 |
| The Value of Life Near its End and Terminal Care |
1 |
1 |
1 |
269 |
1 |
1 |
19 |
783 |
| The Value of Life Near its End and Terminal Care |
0 |
0 |
0 |
230 |
0 |
0 |
6 |
455 |
| The Value of Life in General Equilibrium |
0 |
0 |
0 |
92 |
2 |
2 |
20 |
373 |
| Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs |
0 |
0 |
0 |
136 |
0 |
3 |
19 |
619 |
| Will the AIDS Epidemic be Self-Limiting? Evidence on the Responsiveness of the Demand for Condoms to the Prevalence of AIDS |
0 |
0 |
0 |
1 |
0 |
0 |
6 |
270 |
| Will the AIDS Epidemic be Self-Limiting? Evidence on the Responsiveness of the Demand for Condoms to the Prevalence of AIDS |
0 |
0 |
0 |
40 |
0 |
1 |
8 |
317 |
| Total Working Papers |
2 |
6 |
36 |
9,396 |
27 |
102 |
1,019 |
49,393 |
| Journal Article |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| A Cost-Benefit Analysis of Using Evidence of Effectiveness in Terms of Progression Free Survival in Making Reimbursement Decisions on New Cancer Therapies |
0 |
0 |
0 |
57 |
0 |
0 |
15 |
231 |
| A Reexamination of the Costs of Medical R&D Regulation |
0 |
0 |
1 |
14 |
1 |
1 |
11 |
79 |
| A Theoretical and Empirical Investigation of the Effects of Public Health Subsidies for STD Testing |
0 |
0 |
0 |
136 |
1 |
2 |
9 |
464 |
| Altruism and Innovation in Health Care |
0 |
0 |
0 |
21 |
0 |
2 |
11 |
151 |
| An Empirical Examination of Information Barriers to Trade in Insurance |
0 |
0 |
0 |
222 |
0 |
2 |
22 |
975 |
| An economic evaluation of the war on cancer |
0 |
0 |
2 |
110 |
0 |
0 |
14 |
596 |
| An empirical examination of the implications of assortative matching on the incidence of HIV |
0 |
0 |
0 |
39 |
0 |
0 |
7 |
94 |
| Antitrust in the Not-for-Profit Sector |
0 |
0 |
0 |
114 |
0 |
0 |
14 |
472 |
| Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process |
0 |
0 |
1 |
30 |
1 |
3 |
17 |
322 |
| Can Oral Nutritional Supplements Improve Medicare Patient Outcomes in the Hospital? |
0 |
0 |
0 |
35 |
0 |
0 |
9 |
191 |
| Commentary |
0 |
0 |
0 |
2 |
0 |
0 |
3 |
17 |
| Commentary |
0 |
0 |
0 |
2 |
0 |
1 |
3 |
11 |
| Commentary |
0 |
0 |
0 |
3 |
0 |
0 |
6 |
32 |
| Cost-benefit analysis of the FDA: The case of the prescription drug user fee acts |
0 |
0 |
1 |
147 |
2 |
4 |
33 |
761 |
| Cost-effectiveness analysis and innovation |
0 |
0 |
0 |
112 |
0 |
2 |
16 |
436 |
| Data Markets and the Production of Surveys |
0 |
0 |
0 |
23 |
1 |
1 |
8 |
114 |
| Data Markets, Missing Data, and Incentive Pay |
0 |
0 |
0 |
0 |
1 |
1 |
9 |
191 |
| Defining Value: The Need for a Longer, Broader View |
0 |
0 |
0 |
15 |
1 |
1 |
9 |
70 |
| Desegregation and Social Monopoly Pricing |
0 |
0 |
0 |
2 |
0 |
0 |
4 |
9 |
| Disease Eradication: Private versus Public Vaccination |
0 |
0 |
8 |
424 |
1 |
4 |
34 |
1,082 |
| Does Intellectual Property Restrict Output? An Analysis of Pharmaceutical Markets |
0 |
1 |
1 |
41 |
0 |
2 |
15 |
186 |
| Dynamic information release |
0 |
0 |
0 |
3 |
1 |
1 |
7 |
21 |
| Endogenous cost-effectiveness analysis and health care technology adoption |
0 |
0 |
0 |
18 |
0 |
0 |
4 |
115 |
| Equilibrium and Efficiency in an Organized Vote Market |
0 |
0 |
0 |
0 |
0 |
0 |
10 |
250 |
| Erratum: Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA |
0 |
0 |
0 |
3 |
0 |
2 |
13 |
33 |
| Evaluating an Argument for Affirmative Action |
0 |
0 |
0 |
3 |
0 |
1 |
6 |
19 |
| External Costs of Risky Health Behaviors Associated with Leading Actual Causes of Death in the U.S.: A Review of the Evidence and Implications for Future Research |
0 |
0 |
1 |
1 |
0 |
1 |
7 |
12 |
| Financial Health Economics |
0 |
0 |
0 |
47 |
0 |
2 |
14 |
200 |
| Geographic Variation in Health Care: The Role of Private Markets |
0 |
1 |
1 |
76 |
1 |
2 |
13 |
434 |
| HETEROGENEITY IN ACTION: THE ROLE OF PASSIVE PERSONALIZATION IN COMPARATIVE EFFECTIVENESS RESEARCH |
0 |
0 |
0 |
2 |
0 |
1 |
8 |
33 |
| How Does Technological Change Affect Quality-Adjusted Prices in Health Care? Systematic Evidence from Thousands of Innovations |
0 |
0 |
0 |
14 |
0 |
2 |
11 |
59 |
| How Does Technological Change Affect Quality-Adjusted Prices in Health Care? Systematic Evidence from Thousands of Innovations |
0 |
0 |
1 |
10 |
0 |
2 |
18 |
78 |
| Integrated Insurance Design in the Presence of Multiple Medical Technologies |
0 |
0 |
0 |
23 |
1 |
2 |
13 |
258 |
| Is the Food And Drug Administration Safe And Effective? |
0 |
0 |
0 |
21 |
0 |
0 |
5 |
331 |
| Is the Obesity Epidemic a Public Health Problem? A Review of Zoltan J. Acs and Alan Lyles's Obesity, Business and Public Policy |
0 |
0 |
0 |
27 |
0 |
0 |
18 |
406 |
| Labor Markets in Statistics: The Subject Supply Effect in Medical R&D |
1 |
1 |
1 |
3 |
1 |
4 |
11 |
38 |
| Labor Supply and Weight |
1 |
1 |
2 |
52 |
1 |
1 |
19 |
160 |
| Longevity Complementarities under Competing Risks |
0 |
0 |
0 |
167 |
2 |
4 |
17 |
573 |
| Managed Care and the Quality of Health Care: A Misguided Debate? |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
234 |
| Measurement errors: A principal investigator-agent approach |
0 |
0 |
0 |
38 |
0 |
0 |
2 |
127 |
| Multiple-output agency incentives in data production: experimental evidence |
0 |
0 |
0 |
12 |
0 |
1 |
6 |
64 |
| Old-Age Longevity and Mortality-Contingent Claims |
0 |
0 |
3 |
322 |
1 |
1 |
18 |
866 |
| Pricing and R&D When Consumption Affects Longevity |
0 |
0 |
0 |
0 |
0 |
1 |
6 |
205 |
| Private Vaccination and Public Health: An Empirical Examination for U.S. Measles |
0 |
1 |
1 |
45 |
0 |
1 |
12 |
178 |
| Public Financing and the Market for Long-Term Care |
0 |
0 |
0 |
24 |
0 |
0 |
7 |
107 |
| Public Spending on AIDS Education: An Economic Analysis |
0 |
0 |
0 |
5 |
0 |
0 |
6 |
251 |
| Quantifying Gains in the War on Cancer Due to Improved Treatment and Earlier Detection |
0 |
0 |
0 |
41 |
0 |
0 |
9 |
165 |
| Quantifying the Value of Personalized Medicines: Evidence from COX-2 Inhibitors |
0 |
0 |
0 |
10 |
0 |
0 |
7 |
76 |
| RESPONSE TO EPSTEIN'S COMMENT ON “HETEROGENEITY IN ACTION” |
0 |
0 |
0 |
1 |
0 |
1 |
17 |
35 |
| Rational Epidemics and Their Public Control |
0 |
0 |
0 |
1 |
7 |
11 |
36 |
724 |
| Sharing R&D Risk in Healthcare via FDA Hedges |
0 |
0 |
1 |
4 |
0 |
2 |
17 |
26 |
| Should Global Health be Tailored Toward the Rich? Altruism and Efficient R&D for Neglected Diseases |
0 |
0 |
0 |
7 |
1 |
1 |
8 |
49 |
| Social Welfare and Measurement of Segregation |
0 |
0 |
0 |
71 |
0 |
1 |
9 |
153 |
| Subject Evaluation in Social Experiments |
0 |
0 |
0 |
0 |
0 |
0 |
10 |
383 |
| The Contributions of Improved Therapy and Earlier Detection to Cancer Survival Gains, 1988-2000 |
1 |
1 |
1 |
73 |
1 |
1 |
15 |
311 |
| The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the U.S. Pharmaceuticals Industry |
0 |
0 |
1 |
32 |
0 |
0 |
12 |
297 |
| The Economic Epidemiology of Crime |
0 |
0 |
0 |
46 |
0 |
0 |
8 |
1,104 |
| The Impact of Public Testing for Human Immunodeficiency Virus |
0 |
0 |
1 |
37 |
0 |
0 |
4 |
104 |
| The Option Value of Innovation |
0 |
0 |
1 |
47 |
2 |
2 |
8 |
223 |
| The Quantity and Quality of Life and the Evolution of World Inequality |
1 |
2 |
6 |
721 |
3 |
8 |
68 |
2,432 |
| The Regulation of Medical Innovation and Pharmaceutical Markets |
0 |
0 |
1 |
11 |
1 |
1 |
5 |
31 |
| The Responsiveness of the Demand for Condoms to the Local Prevalence of AIDS |
0 |
0 |
0 |
31 |
4 |
5 |
19 |
185 |
| The Rise in Old-Age Longevity and the Market for Long-Term Care |
0 |
0 |
0 |
106 |
1 |
4 |
18 |
463 |
| The Value of Diagnostic Testing in Personalized Medicine |
0 |
0 |
1 |
61 |
0 |
1 |
7 |
231 |
| The evaluation of new health care technology: The labor economics of statistics |
0 |
0 |
0 |
70 |
0 |
2 |
9 |
366 |
| The growth of obesity and technological change |
0 |
0 |
0 |
32 |
0 |
2 |
35 |
171 |
| The impact of comparative effectiveness research on health and health care spending |
0 |
0 |
0 |
35 |
2 |
2 |
17 |
292 |
| The institute of medicine report on the FDA: where is the science? |
0 |
0 |
0 |
26 |
1 |
3 |
13 |
154 |
| The nonprofit sector and industry performance |
0 |
0 |
4 |
261 |
3 |
5 |
37 |
746 |
| The welfare loss of disease and the theory of taxation |
0 |
0 |
0 |
54 |
0 |
1 |
10 |
151 |
| The world‐wide growth in obesity: an economic research agenda |
0 |
0 |
0 |
9 |
0 |
1 |
10 |
649 |
| Valuing health technologies at nice: recommendations for improved incorporation of treatment value in HTA |
0 |
0 |
0 |
26 |
0 |
0 |
9 |
110 |
| Welfare-Enhancing Technological Change and the Growth of Obesity |
0 |
0 |
0 |
152 |
0 |
0 |
14 |
443 |
| Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs |
0 |
0 |
0 |
115 |
0 |
4 |
36 |
658 |
| `Me-Too' Innovation in Pharmaceutical Markets |
0 |
1 |
1 |
80 |
1 |
3 |
16 |
311 |
| `RATIONAL CHOICE, PUBLIC POLICY AND AIDS' |
0 |
0 |
0 |
0 |
1 |
3 |
7 |
9 |
| Total Journal Articles |
4 |
9 |
42 |
4,625 |
45 |
119 |
1,013 |
22,588 |
LogEc is hosted by the
Örebro University School of Business.